» Articles » PMID: 16239284

Outbreak of Carbapenem-resistant Pseudomonas Aeruginosa Producing SPM-1 Metallo-{beta}-lactamase in a Teaching Hospital in Southern Brazil

Overview
Date 2005 Oct 22
PMID 16239284
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To describe the first nosocomial outbreak of Pseudomonas aeruginosa producing SPM-1 metallo-beta-lactamase (MBL) in southern Brazil.

Patients And Methods: From January to October 2004, carbapenem-resistant P. aeruginosa (CRPA) were recovered from hospitalized patients. Mortality, site of infection/colonization, patient location and susceptibility profiles were analysed. A sample of CRPA was screened for MBL production, evaluated for the presence of bla(SPM-1), bla(IMP-1) and bla(VIM-2) genes by PCR and submitted for molecular typing by DNA macrorestriction.

Results: A total of 135 CRPA (one isolate per patient) were recovered. Two major antibiotic susceptibility profiles comprised 63.7% of the isolates (susceptibility to polymyxin B and aztreonam, and susceptibility only to polymyxin B). Thirty-five CRPA were screened for MBL production (10 isolates from April, June and July, and 25 from September and October) and 27 (77.1%) proved to be positive for MBL production. Twenty-one of the 24 CRPA tested carried the bla(SPM-1) gene. The mortality of patients with CRPA was 48.1% and no variable was associated with death. Molecular typing revealed the presence of a clone with four related subtypes among the bla(SPM-1)-positive CRPA.

Conclusions: The prevalence of MBL production by CRPA is high and horizontal transmission is a major determinant for the spread of SPM-1 CRPA among patients in this institution. As infection control measures failed to control the spread of CRPA, continuous surveillance for MBL production is warranted.

Citing Articles

In search of the best method to detect carriage of carbapenem-resistant Pseudomonas aeruginosa in humans: a systematic review.

Shahab S, van Veen A, Buchler A, Saharman Y, Karuniawati A, Vos M Ann Clin Microbiol Antimicrob. 2024; 23(1):50.

PMID: 38858708 PMC: 11163693. DOI: 10.1186/s12941-024-00707-1.


Acquired and Carbapenemase-Encoding Genes in : A Seven-Year Survey Highlighting an Increasing Epidemiological Threat.

Martinez-Zavaleta M, Fernandez-Rodriguez D, Hernandez-Duran M, Colin-Castro C, Garcia-Hernandez M, Becerra-Lobato N Pathogens. 2023; 12(10).

PMID: 37887772 PMC: 10610504. DOI: 10.3390/pathogens12101256.


Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis.

Almeida M, Freitas M, Folescu T, Firmida M, Carvalho-Assef A, Marques E Curr Microbiol. 2021; 78(2):696-704.

PMID: 33404752 DOI: 10.1007/s00284-020-02337-0.


First Italian outbreak of VIM-producing in an adult polyvalent intensive care unit, August-October 2018: A case report and literature review.

Iovene M, Pota V, Galdiero M, Corvino G, Di Lella F, Stelitano D World J Clin Cases. 2019; 7(21):3535-3548.

PMID: 31750335 PMC: 6854422. DOI: 10.12998/wjcc.v7.i21.3535.


A retrospective analysis of bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections.

Shi Q, Huang C, Xiao T, Wu Z, Xiao Y Antimicrob Resist Infect Control. 2019; 8:68.

PMID: 31057792 PMC: 6485151. DOI: 10.1186/s13756-019-0520-8.